Immune mediation of hypersensitivity adverse drug reactions: Implications for therapy

Expert Opinion on Drug Safety

Volumn 8, Issue 3, 2009, Pages 331-343

  Rieder, Michael J ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b CHILDREN S HOSPITAL OF WESTERN ONTARIO   (Canada)

Author keywords

Adverse drug reactions; Drug hypersensitivity; Immunopharmacology

Indexed keywords

ABACAVIR; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; BRADYKININ; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN A; GRANZYME B; HAPTEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; LAMOTRIGINE; LEUKOTRIENE C4; LOCAL ANESTHETIC AGENT; PENICILLIN G; PERFORIN; PHENYTOIN; PROSTAGLANDIN D2; SULFAMETHOXAZOLE; SULFONAMIDE; T LYMPHOCYTE RECEPTOR; THROMBOCYTE ACTIVATING FACTOR; UNINDEXED DRUG;

ANAPHYLAXIS; ANTIGEN RECOGNITION; CROSS REACTION; DISEASE CLASSIFICATION; DRUG ACETYLATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; ECZEMA; HUMAN; HYPOTHESIS; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; RASH; REVIEW; URTICARIA; VASCULITIS;

ANAPHYLAXIS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; HUMANS; IMMUNOLOGIC FACTORS; URTICARIA;

EID: 67649362266     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330902933736     Document Type: Review

References (129)

1. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-1259 (Pubitemid 30769501)
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-1205 (Pubitemid 28193431)
3. Uetrecht J. Idiosyncratic adverse drug reactions: past, present and future. Chem Res Toxicol 2008;21:89-92 (Pubitemid 351219710)
4. Naisbitt DJ, Pirmohamed M, Park BK. Immunopharmacology of hypersensitivity reactions to drugs. Curr Allergy Asthma Rep 2003;3:22-29
5. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, editor, Textbook of adverse drug reactions. Oxford: Oxford University Press, 1977. p. 10
6. Rieder MJ. Mechanisms of unpredictable adverse drug reactions. Drug Safety 1994;11:196-212 (Pubitemid 24283736)
7. Thien FC. Drug hypersensitivity. Med J Aust 2006;185(6):333-338 (Pubitemid 44515439)
8. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use. Report of the nomenclature review committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;113:832-836 (Pubitemid 38608590)
9. Greenberger PA. 8. Drug allergy. J Allergy Clin Immunol 2006;117(2 Suppl Mini-Primer):S464-70 (Pubitemid 43163460)
10. Kawabata TT, Haggerty HG, Lavin AL, Adkinson NF. Meeting Review: Immune-Mediated Drug Hypersensitivities Reactions (IDHR) Workshop: mechanisms to increase IDHR research opportunities. J Immunotoxicol 2004;1:201-205
11. Rieder MJ. Hypersensitivity adverse drug reactions in children: pathophysiology and therapeutic implications. Curr Ther Res 2001;62(12):913-929 (Pubitemid 34112233)
12. Pirmohammed M. Anticipating, investigating and managing the adverse effects of drugs. Clin Med 2005;5(1):23-26 (Pubitemid 40313725)
13. Zaccara G, Franciotta D, Perucca E. Critical review: idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007;48(7):1223-1244 (Pubitemid 47063067)
14. Coombs PR, Gell PG. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell RR, editor, Clinical aspects of immunology. Oxford University Press, Oxford. 1968. p. 575-596
15. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003;139:683-693 (Pubitemid 38124540)
16. Brockow K, Romano A. Skin tests in the diagnosis of drug hypersensitivity reactions. Curr Pharm Des 2008;14(27):2778-2791
17. Friedmann PS, Lee MS, Friedmann AC, Barnetson RS. Mechanisms in cutaneous drug hypersensitivity reactions. Clin Exp Allergy 2003;33:861-872 (Pubitemid 36851233)
18. Gruchalla RS, Pirmohamed M. Clinical practice: antibiotic allergy. N Engl J Med 2006;354(6):601-609
19. Thyssen JP, Menne T, Elberling J, et al. Hypersensitivity to local anaesthetics - update and proposal of evaluation algorithm. Contact Dermatitis 2008;59(2):69-78
20. Zhao Z, Baldo BA, Baumgart KW, Mallon DF. Fine structural recognition specificities of IgE antibodies distinguishing amoxicillanyl determinants in allergic subjects. J Mol Recognit 2001;14:300-307 (Pubitemid 33055842)
21. Baldo BA, Zhao Z, Pham NM. Antibiotic allergy: immunochemical and clinical considerations. Curr Allergy Asthma Rep 2008;8(1):49-55
22. Buchmiller BL, Khan DA. Evaluation and management of pediatric drug allergy reactions. Curr Allergy Asthma Rep 2007;7(6):402-409 (Pubitemid 47629073)
23. Sheikh A, Shehata YA, Brown SG, Simons FE. Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock. Cochrane Database Syst Rev 2008;8 (4):CD006312
24. Spielberg SP, Gordon GB, Blake DA, et al. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981;305(13):722-727 (Pubitemid 11062054)
25. Shear NH, Spielberg SP. In vitro evaluation of a toxic metabolite of sulfadiazine. Can J Physiol Pharmacol 1985;63(11):1370-1372
26. Shear NH, Spielberg SP, Grant DM, et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986;105(2):179-184 (Pubitemid 16039289)
27. Rieder MJ, Uetrecht J, Shear NH, Spielberg SP. Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J Pharmacol Exp Ther 1988;244(2):724-728 (Pubitemid 18076620)
28. Park BK, Coleman JW, Kitteringham NR. Drug disposition and drug hypersensitivity. Biochem Pharmacol 1987;36:581-590 (Pubitemid 17026072)
29. Speirs RS. Multiple cellular and subcellular responses to antigen. Literature review and hypothesis of immunization. Immunochemistry 1971;8(7):665-689
30. Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J Exp Med 1935;61:643-656
31. Beaune P, Dansette PM, Mansuy D, et al. Human antiendoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987;84:551-555 (Pubitemid 17006233)
32. Uetrecht J. Evaluation of which reactive metabolite, if any, is responsible for a specific idiosyncratic reaction. Drug Metabol Rev 2006;38(4):745-753 (Pubitemid 44903266)
33. Knowles SR, Shapiro LE, Shear NH. Reactive metabolites and adverse drug reactions: clinical considerations. Clin Rev Allergy Immunol 2003;24(3):229-238 (Pubitemid 36584218)
34. Park BK, Naisbitt DJ, Gordon SF, et al. Metabolic activation in drug allergies. Toxicology 2001;158(1-2):11-23 (Pubitemid 32119492)
35. Tschen AC, Rieder MJ, Oyewumi LK, Freeman DS. The cytotoxicity of clozapine metabolites: implications for predicting clozapine-induced agranulocytosis. Clin Pharmacol Ther 1999;65(5):526-532 (Pubitemid 29237326)
36. Tabatabaei AR, Thies RL, Abbott FS. Assessing the mechanism of metabolism-dependent valproic acid-induced in vitro cytotoxicity. Chem Res Toxicol 1999;12(4):323-330 (Pubitemid 29193907)
37. Kearns GL, Wheeler JG, Rieder MJ, Reid J. Serum-sickness like reaction to cefaclor: lack of in vitro cross-reactivity with loracarbef. Clin Pharmacol Ther 1998;63(6):686-693 (Pubitemid 28327897)
38. Uetrecht J, Zahid N, Tehim A, et al. Structural features associated with reactive metabolite formation in clozapine analogues. Chem Biol Interact 1997;104(1-2):117-119 (Pubitemid 27263369)
39. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions - new concepts. Clin Exp Allergy 2007;37:989-999 (Pubitemid 46955519)
40. Pichler W, Beeler A, Keeller M, et al. Pharmacological interaction of drugs with immune receptors with immune receptors: the p-i concept. Allergol Int 2006;55(1):17-25
41. Naisbitt DJ, Britschgi M, Wong G, et al. Hypersensitivity to carbamazepine: characterization of the specificity, phenotype and cytokine profile of drug-specific T cell lines. Mol Pharmacol 2003;63:732-741 (Pubitemid 36297347)
42. Naisbitt DJ, Farrell J, Wong G, et al. Characterization of drug-specific T cells in lamotrigene hypersensitivity. J Allergy Clin Immunol 2003;111:1393-1403 (Pubitemid 36683697)
43. Wu Y, Sanderson JP, Farrell J, et al. Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006;118:233-241 (Pubitemid 43964854)
44. Schnyder B, Mauri-Hellwig D, Zanni M, et al. Direct MHC-dependent presentation of the drug sulfamethoxazole to human αβ T cell clones. J Clin Invest 1997;100:136-141 (Pubitemid 27311251)
45. Schmidt DA, Depta JP, Pichler W. T cell mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. Clin Exp Allergy 2006;36:59-69
46. Zanni MP, Mauri-Hellwig D, Brander C, et al. Characterization of lidocaine-specific T cells. J Immunol 1997;158:1139-1148 (Pubitemid 127469935)
47. Zanni MP, von Greyerz S, Harl Y, et al. Recognition of local anesthetics by αβ T cells. J Invest Dermatol 1999;112:197-204 (Pubitemid 29061976)
48. Depta JP, Altznauer F, Gamerdinger K, et al. Drug interaction with T cell receptors determines degree of cross-reactivity. J Allergy Clin Immunol 2004;113:519-527
49. Zanni MP, von Greyerz S, Schnyder B, et al. HLA-restricted processing - and metabolism-independent pathway of drug recognition by human αβ T lymphocytes. J Clin Invest 1998;102:1591-1598 (Pubitemid 28492227)
50. Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol 1994;12:91-1045 (Pubitemid 24140436)
51. Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the danger hypothesis and innate immune system. Chem Res Toxicol 1999;12(5):387-395 (Pubitemid 29352401)
52. Naisbitt DJ, Gordon SF, Pirmohammed M, Park BK. Immunological principles of adverse drug reactions: the initiation and propogation of immune responses elicited by drug treatment. Drug Saf 2000;23(6):483-507 (Pubitemid 32001512)
53. O'Neill L. Toll-like receptors and the danger hypothesis. Trends Immunol 2001;8:421
54. Sequin B, Uetrecht J. The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol 2003;3(4):235-242 (Pubitemid 37010877)
55. Liu L, Inoue H, Nakayama H, et al. The endogenous danger signal uric acid augments contact hypersensitivity responses in mice. Pathobiology 2007;74(3):177-185 (Pubitemid 47094062)
56. Lu W, Li X, Uetrecht JP. Changes in gene expression induced by carbamazepine and phenytoin: testing the danger hypothesis. J Immunotoxicol 2008;5(2):107-113 (Pubitemid 351882412)
57. Pacitto SR, Uetrecht JP, Boutros PC, Popovic M. Changes in gene expression induced by tienillic acid and sulfamethoxazole: testing the danger hypothesis. J Immunotoxicol 2008;4(4):253-266
58. Hertl M, Jugert F, Merk HF. CD8+ dermal T-cells from a sulfamethoxazole -induced bullous exanthema proliferate in response to drug-modified liver microsomes. Br J Dermatol 1995;132:215-220
59. Mauri-Hellweg D, Bettens F, Mauri D, et al. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfamethoxazole, phenytoin and carbamazepine. J Immunol 1995;155:462-472
60. Hashizume H, Takigawa M, Tokura Y. Characterization of drug-specific T-cells in phenobarbital-induced eruption. J Immunol 2002;168:5359-5368 (Pubitemid 34496005)
61. Yawalkar N, Hari Y, Frutig K, et al. T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J Invest Dermatol 2000;115:647-652 (Pubitemid 30780186)
62. Wu Y, Farrell J, Pirmohamed M, et al. Generation and characterization of antigen specific CD4+, CD8+ and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 2007;119:973-981
63. Sanderson DJ, Naisbitt DJ, Farrell J, et al. Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol 2007;178(9):5533-5542 (Pubitemid 46674348)
64. Naisbitt DJ, Pirmohammed M, Park BK. Immunological principles of T cell mediated adverse drug reactions in skin. Exp Opin Drug Saf 2007;6(2):109-124 (Pubitemid 46380805)
65. Lavergne SN, Park BK, Naisbitt DJ. The roles of drug metabolism in the pathogenesis of T cell mediated drug hypersensitivity. Curr Opin Allergy Clin Immunol 2008;8(4):299-307
66. Evans R, 3rd KIM, K MAHR. Current concepts in allergy: drug reactions. Curr Probl Pediatr 1991;21(5):185-192
67. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002;8(1):5
68. Majumdar S, Mockenhaupt M, Roujeau J, Townshend A. Interventions for toxic epidermal necrolysis. Cochrane Database Syst Rev 2002;(4):CD001435
69. Krivoy N, Taer M, Neuman MG. Antiepileptic drug-induced hypersensitivity syndrome reactions. Curr Drug Saf 2006;1(3):289-299
70. Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy 2007;27(10):1425-1439 (Pubitemid 47530448)
71. Sheridan RL, Weber JM, Schulz JT, et al. Management of severe toxic epidermal necrolysis in children. J Burn Care Rehabil 1999;20(6):497-500 (Pubitemid 30007829)
72. Ringheanu M, Laude TA. Toxic epidermal necrolysis in children - an update. Clin Pediatr (Phila) 2000;39(12):687-694 (Pubitemid 32016871)
73. Spies M, Sanford AP, ili Low JF, et al. Treatment of extensive toxic epidermal necrolysis in children. Pediatr 2001;108(5):1162-1168
74. Sanclemente G, De la Roche CA, Escobar CE, Falabella R. Pentoxyfylline in toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol 1999;38(11):878-879
75. Inamo Y, Okubo T, Wada M, et al. Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients. Three case reports. Int Arch Allergy Immunol 2002;127(1):89-94 (Pubitemid 34224958)
76. Aihara Y, Ito R, Ito S, et al. Toxic epidermal necrolysis in a child successfully treated with cyclosporin A and methylprednisolone. Pediatr Int 2007;49(5):659-662 (Pubitemid 47414919)
77. Chaidemenos GC, Chrysomallis F, Sombolos K, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 1997;36(3):218-221 (Pubitemid 27208324)
78. Egan CA, Grant WJ, Morris SE, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999;40(3):458-461 (Pubitemid 29115308)
79. Trautmann A, Klein CE, Kampgen E, Brocker EB. Severe bullous drug reactions treated successfully with cyclophosphamide. Br J Dermatol 1998;139:1127-1128 (Pubitemid 29010571)
80. Wolkenstein P, Laterjet J, Roujeau JC, et al. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-1589 (Pubitemid 28515243)
81. Mitchell JH. Stevens Johnson syndrome: treatment with corticosteroids. Postgrad Med J 1958;34:384-388
82. Kim PS, Goldfarb IW, Gaisford JC, Slater H. Stevens-Johnson syndrome and toxic epidermal necrolysis: a pathophysiological review with recommendations for a treatment protocol. J Burn Care Rehabil 1983;4:91-100
83. Halebian PH, Corder VJ, Madden MR, et al. Improved burn care survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;204:503-512 (Pubitemid 17176768)
84. Patterson R, Dykewicz MS, Gonzalzles A, et al. Erythema multiforme and Stevens Johnson syndrome: descriptive and therapeutic controversy. Chest 1990;98:331-336 (Pubitemid 20247967)
85. Patterson R, Grammer LC, Greenberger PA, et al. Stevens-Johnson syndrome (SJS): effectiveness of corticosteroids in management and recurrent SJS. Allergy Proc 1992;13(2):89-95
86. Pattterson R, Miller M, Kaplan M, et al. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy 1994;74:27-34 (Pubitemid 24217545)
87. Englelhardt SL, Schurr MJ, Helgerson RB. Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. J Burn Care Rehabil 1997;18:520-524 (Pubitemid 27508548)
88. Kakourou T, Klontza D, Soteropoulou F, Kattamis C. Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. Eur J Pediatr 1997;156(2):90-93 (Pubitemid 27049148)
89. Cheriyan S, Patterson R, Greenberger PA, et al. The outcome of Stevens-Johnson syndrome treated with corticosteroids. Allergy Proc 2000;21:101-105
90. Tripathi A, Ditto AM, Grammer LC, et al. Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc 2000;21(2):101-105
91. Schultz JT, Sheridan RL, Ryan CM, et al. A ten year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000;21:199-204 (Pubitemid 30396349)
92. Bahna SL, Khalili B. New concepts in the management of adverse drug reactions. Allergy Asthma Proc 2007;28(5):517-524
93. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282(5388):490-493 (Pubitemid 28483679)
94. Stur K, Karlhofer FM, Stingl G. Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. J Invest Dermatol 2007;127:802-807 (Pubitemid 46434660)
95. Cazzola G, Nicolussi M, Carraro F. High-dose i.v. 7S immunoglobulin treatment in Stevens-Johnson syndrome. Helvetica Paediatrica Acta 1986;41:87-88
96. Morici MV, Galen WK, Shetty AK, et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. J Rheumatol 2000;27(10):2494-2497 (Pubitemid 30765382)
97. Tristani-Firouzi P, Petersen MJ, Saffle JR, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002;47(4):548-552
98. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatr 2003;112:1430-1436 (Pubitemid 37523435)
99. Prins C, Vittorio C, Padilla RS, et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatol 2003;207(1):96-99
100. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139(1):26-32 (Pubitemid 36091570)
101. Mayorga C, Torres MJ, Corzo JL, et al. Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin. Ann Allergy Asthma Immunol 2003;91(1):86-91 (Pubitemid 36909605)
102. Al-Mutairi N, Arun J, Osama NE, et al. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Internat J Dermatol 2004;43(11):847-851 (Pubitemid 39529949)
103. Mangla K, Rastogi S, Goyal P, et al. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol 2005;71(6):398-400 (Pubitemid 41769422)
104. Arca E, Kose O, Erbil AH, et al. A 2-year-old girl with Stevens-Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin. Pediatr Dermatol 2005;22(4):317-320 (Pubitemid 41583309)
105. Kalyoncu M, Cimsit G, Cakir M, Okten A. Toxic epidermal necrolysis treated with intravenous immunoglobulin and granulocyte colony-stimulating factor. Indian Pediatr 2004;41(4):392-395 (Pubitemid 38525344)
106. Pasic S. Intravenous immunoglobulin in toxic epidermal necrolysis. Int J Dermatol 2006;45(9):1117-1118 (Pubitemid 44317142)
107. Zipitis CS, Thalange N. Intravenous immunoglobulins for the management of Stevens-Johnson syndrome with minimal skin manifestations. Eur J Pediatr 2007;166(6):585-588 (Pubitemid 46643698)
108. Mittmann N, Chan BC, Knowles S, Shear NH. IVIG for the treatment of toxic epidermal necrolysis. Skin Therapy Lett 2007;12(1):7-9
109. Kelemen JJ, Cioffi WG, McManus WF, et al. Burn center care of patients with toxic epidermal necrolysis. J Am Coll Surg 1995;180:273-278
110. Lehrer-Bell KA, Kirsner RS, Tallman PG, Kerdel FA. Treatment of the cutaneous involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis with silver nitrate-impregnated dressings. Arch Dermatol 1998;134(7):877-879 (Pubitemid 28350199)
111. Bannasch H, Kontny U, Kruger M, et al. A semisynthetic bilaminar skin substitute used to treat pediatric full-body toxic epidermal necrolysis: wraparound technique in a 17-month-old girl. Arch Dermatol 2004;140(2):160-162 (Pubitemid 38500326)
112. Asz J, Asz D, Moushey R, et al. Treatment of toxic epidermal necrolysis in a pediatric patient with a nanocrystalline silver dressing. J Pediatr Surg 2006;41(12):e9-12 (Pubitemid 44854974)
113. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988;82(6):1826-1832 (Pubitemid 19054926)
114. Elzaballaai AA, Knowles SR, Rieder MJ, et al. Systematic review of different in vivo and in vitro tests used for the diagnosis of anticonvulsant hypersensitivity syndrome (AHS): I-Patch Test (PT). Drug Saf [In Press]
115. Uetrecht JP. Role of animal models in the study of drug-induced hypersensitivity reactions. AAPS 2006;7(4):e914-21
116. Popovic M, Caswell JL, Mannargudi B, et al. Study of the sequence of events involved in nevaripine-induced skin rash in Brown Norway rats. Chem Res Toxicol 2006;19(9):1205-1214 (Pubitemid 44454037)
117. Chen J, Mannargudi BM, Xu L, Uetrecht J. Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash. Chem Res Toxicol 2008;21(9):1862-1870
118. Rieder MJ, Shear NH, Kanee A, et al. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991;49:13-17
119. Schackman BR, Scott CA, Walensky RP, et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008;22(15):2025-2033
120. Ueta M, Sotozono C, Inatomi T, et al. Association of Fas Ligand gene polymorphism with Stevens-Johnson syndrome. Br J Ophthalmol 2008;92(7):989-991 (Pubitemid 351969685)
121. Vitezica ZG, Milpied B, Lonjou C, et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008;22(4):540-541 (Pubitemid 351317299)
122. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358(6):568-579
123. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18(2):99-107
124. Pirmohamed M, Arbuckle JB, Bowman CE, et al. Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2007;8(12):1661-1691
125. Mann MW, Pons G. Various pharmacogenetic aspects of antiepileptic drug therapy: a review. CNS Drugs 2007;21(2):143-164 (Pubitemid 46247819)
126. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome ...: ethnicity matters. Pharmacogenomics J 2006;6(4):265-268
127. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102(11):4134-4139 (Pubitemid 40388568)
128. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428(6982):486
129. Giacomini KM, Krauss RM, Roden DM, et al. When good drugs go bad. Nature 2007;446:975-977 (Pubitemid 46676037)